ATE482711T1 - Kombinationsprodukt mit einem antagonisten oder inversen agonisten von histamine-rezeptor h3 und einem antipsychotischen oder antidepressiven mittel, und ihre verwendung zur herstellung eines medikaments zur verhinderung der nachteiligen wirkungen von psychotropika - Google Patents
Kombinationsprodukt mit einem antagonisten oder inversen agonisten von histamine-rezeptor h3 und einem antipsychotischen oder antidepressiven mittel, und ihre verwendung zur herstellung eines medikaments zur verhinderung der nachteiligen wirkungen von psychotropikaInfo
- Publication number
- ATE482711T1 ATE482711T1 AT04767475T AT04767475T ATE482711T1 AT E482711 T1 ATE482711 T1 AT E482711T1 AT 04767475 T AT04767475 T AT 04767475T AT 04767475 T AT04767475 T AT 04767475T AT E482711 T1 ATE482711 T1 AT E482711T1
- Authority
- AT
- Austria
- Prior art keywords
- antagonist
- inverse agonist
- antipsychotic
- psychotropics
- medication
- Prior art date
Links
- 230000000694 effects Effects 0.000 title abstract 7
- 239000005557 antagonist Substances 0.000 title abstract 4
- 229940125425 inverse agonist Drugs 0.000 title abstract 4
- 230000000561 anti-psychotic effect Effects 0.000 title abstract 3
- 239000000935 antidepressant agent Substances 0.000 title abstract 3
- 239000003814 drug Substances 0.000 title abstract 3
- 102100032508 Histamine H3 receptor Human genes 0.000 title 1
- 101001016833 Homo sapiens Histamine H3 receptor Proteins 0.000 title 1
- 230000002411 adverse Effects 0.000 title 1
- 239000000164 antipsychotic agent Substances 0.000 title 1
- 239000013066 combination product Substances 0.000 title 1
- 229940127555 combination product Drugs 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
- 229940001470 psychoactive drug Drugs 0.000 title 1
- 239000004089 psychotropic agent Substances 0.000 title 1
- 102000004384 Histamine H3 receptors Human genes 0.000 abstract 2
- 108090000981 Histamine H3 receptors Proteins 0.000 abstract 2
- 230000001430 anti-depressive effect Effects 0.000 abstract 2
- 229940005513 antidepressants Drugs 0.000 abstract 2
- 230000001629 suppression Effects 0.000 abstract 2
- 206010010904 Convulsion Diseases 0.000 abstract 1
- 206010039897 Sedation Diseases 0.000 abstract 1
- 230000036626 alertness Effects 0.000 abstract 1
- 230000037396 body weight Effects 0.000 abstract 1
- 230000036461 convulsion Effects 0.000 abstract 1
- 206010015037 epilepsy Diseases 0.000 abstract 1
- 230000036280 sedation Effects 0.000 abstract 1
- 230000004584 weight gain Effects 0.000 abstract 1
- 235000019786 weight gain Nutrition 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Hydrogenated Pyridines (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0307836A FR2856596B1 (fr) | 2003-06-27 | 2003-06-27 | Nouvelle association medicamenteuse psychiatrique et utilisation d'une antagoniste ou agoniste inverse du recepteur h3 de l'histamine pour preparer un medicament prevenant des effets indesirables de psychotropes. |
| PCT/FR2004/001628 WO2005000315A1 (fr) | 2003-06-27 | 2004-06-25 | Association d'un antagoniste ou agoniste inverse du recepteur h3 de l'histamine avec un anti-psychotique ou un antidepresseur et son utilisation pour preparer un medicament prevenant des effets indesirables de medicaments psychotropes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE482711T1 true ATE482711T1 (de) | 2010-10-15 |
Family
ID=33515484
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04767475T ATE482711T1 (de) | 2003-06-27 | 2004-06-25 | Kombinationsprodukt mit einem antagonisten oder inversen agonisten von histamine-rezeptor h3 und einem antipsychotischen oder antidepressiven mittel, und ihre verwendung zur herstellung eines medikaments zur verhinderung der nachteiligen wirkungen von psychotropika |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US8106041B2 (de) |
| EP (1) | EP1641461B1 (de) |
| JP (1) | JP4800936B2 (de) |
| KR (1) | KR20060094847A (de) |
| AT (1) | ATE482711T1 (de) |
| CA (1) | CA2530381C (de) |
| CY (1) | CY1110947T1 (de) |
| DE (1) | DE602004029364D1 (de) |
| DK (1) | DK1641461T3 (de) |
| ES (1) | ES2350103T3 (de) |
| FR (1) | FR2856596B1 (de) |
| MX (1) | MXPA05013877A (de) |
| PL (1) | PL1641461T3 (de) |
| PT (1) | PT1641461E (de) |
| SI (1) | SI1641461T1 (de) |
| WO (1) | WO2005000315A1 (de) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR048134A1 (es) * | 2003-12-15 | 2006-04-05 | Lundbeck & Co As H | La combinacion de un inhibidor de la recaptacion de serotonina y un antagonista del receptor de la histamina 3, el agonista inverso o el agonista parcial |
| US20050215640A1 (en) | 2004-03-26 | 2005-09-29 | Baxter Jeffrey H | HMB compositions and uses thereof |
| US7487265B2 (en) * | 2004-04-16 | 2009-02-03 | Sandisk Corporation | Memory card with two standard sets of contacts and a hinged contact covering mechanism |
| EP1707203A1 (de) * | 2005-04-01 | 2006-10-04 | Bioprojet | Verwendung von Alkylaminen, die kein Imidazole enthalten, als Histamin H3 Rezeptor Liganden, zur Behandlung von Morbus Parkinson, obstruktiver Schlafapnoe, vaskularer Demenz, Demenz mit Lewy Korpen |
| EP1717233A1 (de) * | 2005-04-29 | 2006-11-02 | Bioprojet | Liganden für den Histamin H3-Rezeptor und ihre therapeutische Anwendung |
| US7831915B2 (en) | 2005-11-10 | 2010-11-09 | Microsoft Corporation | Dynamically protecting against web resources associated with undesirable activities |
| CA2632262C (en) | 2005-12-19 | 2015-04-07 | Abbott Laboratories | Method of using .beta.-hydroxy-.beta.-methylbutyrate |
| US9108948B2 (en) | 2006-06-23 | 2015-08-18 | Abbvie Inc. | Cyclopropyl amine derivatives |
| MX2008016343A (es) | 2006-06-23 | 2009-01-19 | Abbott Lab | Derivados ciclopropil amina como moduladores del receptro de histamina h3. |
| FR2903904A1 (fr) * | 2006-07-21 | 2008-01-25 | Bioprojet Soc Civ Ile | Association de modafinil et d'un antagoniste ou agoniste inverse du recepteur h3 |
| WO2008157094A1 (en) * | 2007-06-13 | 2008-12-24 | Cypress Bioscience, Inc. | Improving the tolerability of mirtazapine and a second active by using them in combination |
| US9186353B2 (en) | 2009-04-27 | 2015-11-17 | Abbvie Inc. | Treatment of osteoarthritis pain |
| EP2461704B1 (de) | 2010-01-29 | 2013-10-09 | Abbott Laboratories | Aseptisch verpackte nahrungsflüssigkeiten mit hmb |
| BR112012017690A2 (pt) | 2010-01-29 | 2015-09-01 | Abbott Lab | Emulsões nutricionais compreendendo hmb de cálcio |
| US9693577B2 (en) | 2010-01-29 | 2017-07-04 | Abbott Laboratories | Method of preparing a nutritional powder comprising spray dried HMB |
| TWI526161B (zh) | 2010-06-10 | 2016-03-21 | 亞培公司 | 包含鈣ｈｍｂ及可溶性蛋白質之實質上透明營養液 |
| US8853390B2 (en) | 2010-09-16 | 2014-10-07 | Abbvie Inc. | Processes for preparing 1,2-substituted cyclopropyl derivatives |
| JO3637B1 (ar) | 2015-04-28 | 2020-08-27 | Janssen Sciences Ireland Uc | مركبات بيرازولو- وترايازولو- بيريميدين مضادة للفيروسات rsv |
| TW201932470A (zh) | 2017-11-29 | 2019-08-16 | 愛爾蘭商健生科學愛爾蘭無限公司 | 具有抗ｒｓｖ活性之吡唑并嘧啶 |
| AU2019216260B2 (en) | 2018-01-31 | 2023-03-02 | Janssen Sciences Ireland Unlimited Company | Cycloalkyl substituted pyrazolopyrimidines having activity against RSV |
| ES2957316T3 (es) | 2018-04-23 | 2024-01-17 | Janssen Sciences Ireland Unlimited Co | Compuestos heteroaromáticos que tienen actividad contra VSR |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2732017B1 (fr) * | 1995-03-21 | 2000-09-22 | Inst Nat Sante Rech Med | Nouveaux derives de l'imidazole antagonistes et/ou agonistes du recepteur h3 de l'histamine, leur preparation et leurs applications therapeutiques |
| EP0982300A3 (de) * | 1998-07-29 | 2000-03-08 | Societe Civile Bioprojet | Alkylamine ohne Imidazolring als Histamin-H3-antagonisten und deren therapeutische Anwendung |
| US20030096808A1 (en) * | 1999-03-29 | 2003-05-22 | Jon M. Miller | Substance to prevent or reverse weight gain induced by psychoactive agents |
| EP1189662A1 (de) * | 1999-06-09 | 2002-03-27 | Eli Lilly And Company | Kombination zur behandlung von antipsychotikumsgebrauch-assozierte gewichtszunahme, enthaltend ein atypisches antipsychotikum und ein h2-antagonist |
| PT1313721E (pt) * | 2000-08-08 | 2006-06-30 | Ortho Mcneil Pharm Inc | Ariloxialquilaminas nao imidazoles como ligandos de receptor h3 |
-
2003
- 2003-06-27 FR FR0307836A patent/FR2856596B1/fr not_active Expired - Fee Related
-
2004
- 2004-06-25 JP JP2006516331A patent/JP4800936B2/ja not_active Expired - Fee Related
- 2004-06-25 SI SI200431513T patent/SI1641461T1/sl unknown
- 2004-06-25 ES ES04767475T patent/ES2350103T3/es not_active Expired - Lifetime
- 2004-06-25 AT AT04767475T patent/ATE482711T1/de active
- 2004-06-25 WO PCT/FR2004/001628 patent/WO2005000315A1/fr not_active Ceased
- 2004-06-25 DK DK04767475.9T patent/DK1641461T3/da active
- 2004-06-25 KR KR1020057024963A patent/KR20060094847A/ko not_active Ceased
- 2004-06-25 PT PT04767475T patent/PT1641461E/pt unknown
- 2004-06-25 DE DE602004029364T patent/DE602004029364D1/de not_active Expired - Lifetime
- 2004-06-25 MX MXPA05013877A patent/MXPA05013877A/es active IP Right Grant
- 2004-06-25 EP EP04767475A patent/EP1641461B1/de not_active Expired - Lifetime
- 2004-06-25 PL PL04767475T patent/PL1641461T3/pl unknown
- 2004-06-25 US US10/562,396 patent/US8106041B2/en active Active
- 2004-06-25 CA CA2530381A patent/CA2530381C/fr not_active Expired - Lifetime
-
2010
- 2010-11-24 CY CY20101101070T patent/CY1110947T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2350103T3 (es) | 2011-01-18 |
| FR2856596B1 (fr) | 2007-04-27 |
| KR20060094847A (ko) | 2006-08-30 |
| MXPA05013877A (es) | 2006-03-13 |
| PL1641461T3 (pl) | 2011-02-28 |
| SI1641461T1 (sl) | 2010-12-31 |
| DE602004029364D1 (de) | 2010-11-11 |
| EP1641461A1 (de) | 2006-04-05 |
| CA2530381C (fr) | 2013-03-12 |
| FR2856596A1 (fr) | 2004-12-31 |
| PT1641461E (pt) | 2010-10-13 |
| WO2005000315A1 (fr) | 2005-01-06 |
| CA2530381A1 (fr) | 2005-01-06 |
| DK1641461T3 (da) | 2011-01-10 |
| US20060210624A1 (en) | 2006-09-21 |
| CY1110947T1 (el) | 2015-06-10 |
| US8106041B2 (en) | 2012-01-31 |
| JP2007516160A (ja) | 2007-06-21 |
| JP4800936B2 (ja) | 2011-10-26 |
| EP1641461B1 (de) | 2010-09-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE482711T1 (de) | Kombinationsprodukt mit einem antagonisten oder inversen agonisten von histamine-rezeptor h3 und einem antipsychotischen oder antidepressiven mittel, und ihre verwendung zur herstellung eines medikaments zur verhinderung der nachteiligen wirkungen von psychotropika | |
| PH12012501480A1 (en) | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| MA38380A1 (fr) | Inhibiteurs quinazoline de l'activation des formes mutantes du récepteur de croissance épidermique (egfr) | |
| EP2331095A4 (de) | Bestimmte kynurenin-3-monooxygenase-inhibitoren, pharmazeutische zusammensetzungen und anwendungsverfahren dafür | |
| MX2010009623A (es) | Derivados de 1-bencil-3-hidroximetilindazol novedosos y su uso en el tratamiento de enfermedades basadas en la expresion de mcp-1, cx3cr1 y p40. | |
| IS8502A (is) | Azatvíhringja heteróhringir sem kannabínóíð-viðtakastillar | |
| DE602005018763D1 (de) | Dopamin-agonisten-kombinationstherapie mit sedativa zur verbesserung der schlafqualität | |
| DE59907752D1 (de) | Verwendung von erythropoietin oder erythropoietin-derivaten zur behandlung von cerebralen ischämien | |
| MX2010009625A (es) | Derivados de 1-bencil-3-hidroximetilindazol y uso de los mismos en el tratamiento de enfermedades basadas en la expresion de mcp-1, cx3cr1 y p40. | |
| ATE454372T1 (de) | Am histamin-h3-rezeptor wirksame mittel, herstellung und therapeutische anwendungen | |
| EA201270144A1 (ru) | Комбинированная терапия при лечении диабета | |
| BRPI0418099A (pt) | compostos, composição farmacêutica, e uso de um composto | |
| DE60326370D1 (de) | Verwendung von cgrp-antagonisten-verbindungen zur behandlung von psoriasis | |
| EP4520398A3 (de) | Behandlung von prostatakrebs | |
| BR0315777A (pt) | Uso de derivados de piperazina como antagonistas ccr1 | |
| WO2009109654A3 (en) | 1-benzyl-3-hydr0xymethylindaz0le derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cxcr1 and p40 | |
| TN2020000160A1 (en) | CHROMANE, ISOCHROMANE AND DIHYDROISOBENZOFURAN DERIVATIVES AS mGIuR2-NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS, AND THEIR USE | |
| DE602004015089D1 (de) | Pyrroloimidazolderivate ,verfahern zu ihrer herstellung, diese enthaltende zusammensetzungen, und ihre verwendung als nootropika | |
| MX2023000610A (es) | Inhibidor de trpv4 como agente terapeutico para enfermedades oculares. | |
| MXPA05007389A (es) | Metodo para el tratamiento de la deficiencia cognitiva debido a la privacion de sueno y estres. | |
| EP1262197A3 (de) | Kombinationstherapie zur Behandlung von Schlafstörungen, Schlaflosigkeit inbegriffen | |
| DE60229240D1 (de) | Verwendung eines analoges des vitamins d3 zur behandlung des autoimmunen diabetes | |
| GEP20257771B (en) | Compounds and compositions as sppl2a inhibitors | |
| MX376381B (es) | Composiciones sinergicas que comprenden dimiracetam (r) (1) y dimiracetam (s) (2) en una proporcion no racemica | |
| ATE445401T1 (de) | Verwendung von opioid-rezeptorantagonisten zur prävention und/oder behandlung von erkrankungen im zusammenhang mit dem target calcineurin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1641461 Country of ref document: EP |